| Today’s Big NewsFeb 4, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now. 
|
|
| By Nick Paul Taylor Pfizer tallied up $1.2 billion in impairment charges in response to changes in development plans and commercial forecasts for Seagen-acquired ADCs. |
|
|
|
By James Waldron Astellas is preparing a significant shake-up of its top tier roles, including ushering out its current Chief Scientific Officer and Chief Manufacturing Officer. |
By Nick Paul Taylor Omega Therapeutics has almost reached the end. With cash running low, the Novo Nordisk-partnered biotech has struck a deal with Flagship Pioneering that could see it file for bankruptcy and lay off up to 17 people. |
By James Waldron Four months after laying off 60% of its workforce, Turnstone Biologics is planning further redundancies as the biotech gives up on its last remaining clinical-stage candidate over manufacturing costs. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
By Darren Incorvaia The Centers for Disease Control and Prevention has asked its staff to withdraw any scientific papers currently under consideration for internal or external publication so that certain words can be removed, according to several reports. |
By Eric Sagonowsky HHS secretary nominee Robert F. Kennedy Jr. is one step closer to confirmation as the Senate Finance Committee voted on Tuesday to advance his nomination for a full Senate vote. |
By James Waldron Cumberland Pharmaceuticals’ Duchenne muscular dystrophy drug has improved the amount of blood pumped by the heart, hitting the main goal of a phase 2 trial. |
By Darren Incorvaia Charles River is shuttering its pathology facility in Durham, North Carolina, after determining the site “is not a strategic fit,” a company spokesperson confirmed to Fierce Biotech in an email. |
By Conor Hale The news comes just days after Baxter completed the sale of its Vantive kidney care unit through a $3.8 billion deal with the Carlyle Group that had been in the works since last summer. |
By Heather Landi Most hospital finance executives surveyed said they will need to shift increased costs onto insurers and patients in the form of higher service charges. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we zoom in on a Fierce JPM Week panel of industry experts discussing what it will take for biotechs to pull off a successful IPO in 2025. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
